ALRN | Jotup

Aileron Therapeutics to Present at Two Upcoming Investor Conferences

Retrieved on:

Lunedì, Maggio 6, 2024

AUSTIN, Texas, May 06, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that Brian Windsor, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences:

Key Points:

AUSTIN, Texas, May 06, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that Brian Windsor, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences:
A live webcast of the events can be accessed at https://investors.aileronrx.com/events-presentations/investor-events .
Replays of the webcasts will be available for 90 days following the presentations.

Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million

Retrieved on:

Venerdì, Maggio 3, 2024

Titan, Sale, Idiopathic pulmonary fibrosis, Prospectus, Aileron, ALRN, Security (finance), Form, Exercise, Patient, Fibrosis, S-3, Therapy

Each share of common stock and accompanying warrant were sold together at a combined public offering price of $4.68.

Key Points:

Each share of common stock and accompanying warrant were sold together at a combined public offering price of $4.68.
The aggregate gross proceeds of the offering were approximately $20 million, before deducting underwriting discounts and commissions and other offering expenses payable by Aileron, and excluding any proceeds that may be received from exercise of the warrants.
Titan Partners Group, a division of American Capital Partners, acted as sole book-running manager for the offering.
The offering was made only by means of a prospectus supplement and the accompanying prospectus that form a part of the registration statement.

Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on:

Lunedì, Aprile 15, 2024

AUSTIN, Texas, April 15, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”, the “Company”, “we”, “our” or “us”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.

Key Points:

We expect to report topline results from the ongoing Phase 1b study of LTI-03 in the third quarter of this year.
Net Loss: Net loss for the quarter ended December 31, 2023, was $7.3 million, compared to $4.5 million for the quarter ended December 31, 2022.
The basic and diluted net loss per share for the quarter ended December 31, 2023 was $1.54 compared to $1.00 for the quarter ended December 31, 2022.
The basic and diluted net loss per share for the full-year 2023 was $3.42 compared to $6.02 for the full-year 2022.

Aileron Therapeutics Announces CEO Transition

Retrieved on:

Martedì, Marzo 12, 2024

Science, Acquisition, ALRN, University, Doctor of Philosophy, Fibrosis, Therapy, Management

WALTHAM, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that current President and Chief Operating Officer, Brian Windsor, Ph.D., has been appointed President and Chief Executive Officer (CEO) and will join the Board of Directors, effective March 11, 2024. Dr. Windsor succeeds Manuel Aivado, M.D., Ph.D., who has stepped down as CEO and will continue to serve on the Company’s Board of Directors. The transition follows the Company’s acquisition of Lung Therapeutics, Inc. (“Lung”) in October of last year.

Key Points:

Dr. Windsor succeeds Manuel Aivado, M.D., Ph.D., who has stepped down as CEO and will continue to serve on the Company’s Board of Directors.
The transition follows the Company’s acquisition of Lung Therapeutics, Inc. (“Lung”) in October of last year.
Prior to Aileron, he served as President, CEO and director of Lung.
“I am honored to assume the role of CEO of Aileron, and am encouraged for its promising future,” said Dr. Windsor.

Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event

Retrieved on:

Giovedì, Febbraio 15, 2024

IPF, University of Alabama, ALRN, CAV-1, Idiopathic pulmonary fibrosis, ID, Weill Cornell Medicine, Doctor of Philosophy, University, Therapy, Webcast, Patient, Fibrosis, Disease, University of Giessen, Pharmaceutical industry

ET titled “Clinical Perspectives on Treating Idiopathic Pulmonary Fibrosis” featuring pulmonary care experts Fernando J. Martinez, M.D., M.S.

Key Points:

ET titled “Clinical Perspectives on Treating Idiopathic Pulmonary Fibrosis” featuring pulmonary care experts Fernando J. Martinez, M.D., M.S.
“As practicing clinicians and experts in pulmonary care medicine, these key opinion leaders bring valuable experience to the discussion of LTI-03 as a potential treatment option for patients with IPF,” said Cory Hogaboam, Ph.D., Chief Scientist of Aileron.
Studies conducted by Aileron and third parties have demonstrated that Cav1 is a key protein in the regulation of lung fibrosis that has a decreased expression in IPF patients.
A replay of the webcast will be available following the completion of the event.

Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024

Retrieved on:

Giovedì, Febbraio 1, 2024

University of Giessen, Intensive care medicine, Physician, Therapy, Fibrosis, Aileron, ID, ALRN, Webcast, Interstitial, Internal

WALTHAM, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it will host a virtual key opinion leader event titled, “Clinical Perspectives on Treating Idiopathic Pulmonary Fibrosis” on Thursday, February 15, 2024, from 4:30 to 5:30 p.m.

Key Points:

WALTHAM, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it will host a virtual key opinion leader event titled, “Clinical Perspectives on Treating Idiopathic Pulmonary Fibrosis” on Thursday, February 15, 2024, from 4:30 to 5:30 p.m.
Aileron management will be joined by pulmonary care medicine experts including:
Andreas Günther, M.D., Senior Physician of Pulmonology and Intensive Care Medicine and Chief Physician of Pulmonology and Internal Intensive Care Medicine at Agaplesion Evang.
To access the event, please dial +1 646-876-9923 (domestic) or +44 208-080-6591 (international) and reference webinar ID: 953 9620 1729 and passcode: 554257 when prompted by the operator.
A replay of the webcast will be available following the completion of the event.

Aileron Therapeutics Announces Acquisition of Lung Therapeutics

Retrieved on:

Martedì, Ottobre 31, 2023

WALTHAM, Mass. and AUSTIN, Texas, Oct. 31, 2023 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN) today announced it has acquired Lung Therapeutics, Inc. ("Lung Tx"), a privately held biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications that have no approved or limited effective treatments. Immediately following the acquisition of Lung Tx, Aileron entered into a definitive agreement for the sale of shares of Aileron's Series X non-voting convertible preferred stock (the "Series X preferred stock") and warrants to purchase shares of Aileron's common stock in a private placement to a group of accredited investors led by Bios Partners ("Bios"), and including Nantahala Capital, as well as additional undisclosed investors. The private placement is expected to result in gross proceeds to Aileron of approximately $18 million before deducting placement agent fees and other offering expenses. Aileron intends to use the proceeds from the private placement primarily to complete the ongoing Phase 1b clinical study of LTI-03, a Caveolin-1-related peptide in development for the treatment of IPF, and for general corporate purposes.

Key Points:

and AUSTIN, Texas, Oct. 31, 2023 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN) today announced it has acquired Lung Therapeutics, Inc. ("Lung Tx"), a privately held biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications that have no approved or limited effective treatments.
"We are pleased to announce that after a thorough evaluation of strategic alternatives, we have completed the acquisition of Lung Therapeutics, which we believe represents a value-creation opportunity for Aileron's stockholders.
"Lung Therapeutics has built a promising clinical-stage pipeline for life-threatening lung conditions, and we believe in the ability of our combined companies to deliver value to both patients and stockholders."
I want to thank the board and entire team of Lung Therapeutics for all their hard work with this transaction."

Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives

Retrieved on:

Martedì, Febbraio 21, 2023

BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in patients with p53-mutated breast cancer showed that patients in the trial experienced severe neutropenia (Grade 4) and alopecia.

Key Points:

BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in patients with p53-mutated breast cancer showed that patients in the trial experienced severe neutropenia (Grade 4) and alopecia.
Based on these findings, Aileron has decided to terminate the Phase 1b breast cancer trial and further development of ALRN-6924.
Aileron also announced that it is exploring a range of strategic alternatives to maximize shareholder value.
The company plans to retain the remaining employees to assist in executing the strategic alternatives review process.

Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements

Retrieved on:

Mercoledì, Novembre 30, 2022

ALRN, Aileron, Therapy, Patient, Security (finance), Annual report, Cancer, Coronavirus, Form 10-K, Pharmaceutical industry

Nasdaq staff made this determination after Ailerons closing bid price was above$1.00per share for 10 consecutive business days from November 11, 2022 to November 25, 2022.

Key Points:

Nasdaq staff made this determination after Ailerons closing bid price was above$1.00per share for 10 consecutive business days from November 11, 2022 to November 25, 2022.
Aileron is a clinical stage chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients lives.
ALRN-6924, our first-in-class MDM2/MDMX dual inhibitor, is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle.
Our targeted strategy is designed to selectively protect multiple healthy cell types throughout the body from chemotherapy without protecting cancer cells.

Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split

Retrieved on:

Giovedì, Novembre 10, 2022

GLOBE, Nasdaq, Aileron, Bangladesh Securities and Exchange Commission, Annual report, Computershare, Private Securities Litigation Reform Act, ALRN, Therapy, CUSIP, Exercise, Coronavirus, Compliance, Cancer, Form 10-K, Patient, Security (finance), Trust, Pharmaceutical industry

The new CUSIP number for the companys common stock following the reverse stock split will be 00887A 204.

Key Points:

The new CUSIP number for the companys common stock following the reverse stock split will be 00887A 204.
No fractional shares of common stock will be issued as a result of the reverse stock split.
The reverse stock split will affect all stockholders uniformly and will not alter any stockholders percentage interest in Ailerons equity, except to the extent that the reverse stock split would result in a stockholder owning a fractional share.
Stockholders owning shares via a broker, bank, trust, or other nominee will have their positions automatically adjusted to reflect the reverse stock split, subject to such broker's particular processes, and will not be required to take any action in connection with the reverse stock split.